Table 1.
Patient characteristics
| Characteristics | (n = 287) |
|---|---|
| Age (y), median (range) | 46 (18‐71) |
| Male, n (%) | 167 (58) |
| Baseline disease, n (%) | |
| AL/MDS/MPD | 189 (66) |
| Lymphoid disorders | 92 (32) |
| Others | 6 (2) |
| Disease status at transplant, n (%) | |
| CR | 203(71) |
| PR | 34 (12) |
| Refractory/active disease | 50 (17) |
| Prior ASCT, n (%) | 67 (23) |
| Period of transplant, n (%) | |
| 2017‐2018 | 89 (31) |
| 2015‐2016 | 75 (26) |
| 2013‐2014 | 79 (28) |
| 2011‐2012 | 23 (8) |
| 2008‐2010 | 21 (7) |
| Conditioning regimen, n (%) | |
| RIC | 135 (47) |
| Type of donor, n (%) | |
| HLA‐identical sibling donor | 105 (37) |
| Unrelated donor | 69 (24) |
| Umbilical cord blood | 52 (18) |
| Haplo‐identical family donor | 61 (21) |
| PB stem cell source, n (% | 228 (79) |
| HLA fully matched, n (%) | 167 (58) |
| ATG as a part of the conditioning regimen, n (%) | 66 (23) |
| GvHD prophylaxis, n (%) | |
| Sir‐Tac | 31 (11) |
| CsA + MTX | 73 (25) |
| Post‐Cy | 116 (40) |
| CsA + PDN and Others | 67 (23) |
| Number of recipients with CARVs per seasons, n (%) | |
| 2018‐2019 | 13 (5) |
| 2017‐2018 | 90 (31) |
| 2016‐2017 | 39 (14) |
| 2015‐2016 | 30 (10) |
| 2014‐2015 | 59 (20) |
| 2013‐2014 | 56 (20) |
| Number of CARV episodes | 597 |
| Number of LRTD CARV episodes | 203 |
| Median time from allo‐HSCT to CARV, days (range) | 198 (−7 to 6177) |
| Number of recipients with IFD after CARVs, n (%) | 29 (10) |
| Median time from CARV to IFD, days (range) | 21 (0‐158) |
| Median time from allo‐HSCT to IFD, days (range) | 211 (20‐989) |
| Median F‐up after CARV, days (range) | 285 (1‐3106) |
Abbreviations: AL, acute leukemia; allo‐HSCT, allogeneic hematopoietic stem cell transplantation; ASCT, autologous stem cell transplantation; ATG, antithymocyte globulin; CARV, community‐acquired respiratory virus; CR, complete remission; CsA, cyclosporine A; F‐up, follow‐up; IFD, invasive pulmonary infectious fungal disease; LRTD, lower respiratory tract disease; MDS, myelodysplastic syndrome; MPD, myeloproliferative disease; MTX, methotrexate; PDN, prednisone; Post‐Cy, post‐transplant cyclophosphamide; PR, partial remission; RIC, reduced intensity conditioning; Sir, sirolimus; Tac, tacrolimus.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.